Merck & Co., Inc. (MRK)
147.74
+0.79
(+0.54%)
USD |
NYSE |
Nov 13, 16:00
147.74
0.00 (0.00%)
After-Hours: 17:03
Merck Enterprise Value : 406.57B for Nov. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 12, 2026 | 406.57B |
| November 11, 2026 | 407.14B |
| November 10, 2026 | 409.28B |
| November 09, 2026 | 411.04B |
| November 06, 2026 | 406.03B |
| November 05, 2026 | 406.55B |
| November 04, 2026 | 414.98B |
| November 03, 2026 | 400.95B |
| November 02, 2026 | 410.05B |
| October 30, 2026 | 412.91B |
| October 29, 2026 | 405.04B |
| October 28, 2026 | 391.72B |
| October 27, 2026 | 393.92B |
| October 26, 2026 | 390.93B |
| October 23, 2026 | 402.43B |
| October 22, 2026 | 407.29B |
| October 21, 2026 | 413.80B |
| October 20, 2026 | 409.90B |
| October 19, 2026 | 398.38B |
| October 16, 2026 | 404.10B |
| October 15, 2026 | 402.23B |
| October 14, 2026 | 407.61B |
| October 13, 2026 | 394.31B |
| October 12, 2026 | 402.87B |
| October 09, 2026 | 403.24B |
| Date | Value |
|---|---|
| October 08, 2026 | 395.30B |
| October 07, 2026 | 396.31B |
| October 06, 2026 | 394.21B |
| October 05, 2026 | 388.29B |
| October 02, 2026 | 400.03B |
| October 01, 2026 | 398.82B |
| September 30, 2026 | 402.52B |
| September 29, 2026 | 415.29B |
| September 28, 2026 | 413.84B |
| September 25, 2026 | 414.06B |
| September 24, 2026 | 412.08B |
| September 23, 2026 | 412.33B |
| September 22, 2026 | 419.32B |
| September 21, 2026 | 415.84B |
| September 18, 2026 | 409.34B |
| September 17, 2026 | 410.04B |
| September 16, 2026 | 404.51B |
| September 15, 2026 | 401.74B |
| September 14, 2026 | 404.36B |
| September 11, 2026 | 402.09B |
| September 10, 2026 | 404.01B |
| September 09, 2026 | 410.97B |
| September 08, 2026 | 413.27B |
| September 04, 2026 | 417.89B |
| September 03, 2026 | 422.85B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Johnson & Johnson | 709.89B |
| Eli Lilly & Co. | 1.388T |
| Pfizer Inc. | 213.03B |
| Bristol Myers Squibb Co. | 159.61B |
| Abbott Laboratories | 213.21B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 5.067B |
| Revenue (Quarterly) | 18.12B |
| Total Expenses (Quarterly) | 13.06B |
| EPS Diluted (Quarterly) | 2.044 |
| Gross Profit Margin (Quarterly) | 71.65% |
| Profit Margin (Quarterly) | 27.96% |
| Earnings Yield | 0.66% |
| Operating Earnings Yield | 3.38% |
| Normalized Earnings Yield | 2.022 |